Nicholas Antos MD
Clinical Expertise
AsthmaCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorNeonatal ScreeningLeadership Positions
Director, Pediatric Cystic Fibrosis ProgramMedical Director, SE Wisconsin School-based Asthma Management ProgramDirector, Cystic Fibrosis CenterPublications (26)
Reply. (Lee-Kim Y, DelSignore L, Antos NJ, Morse CL, Kruger SJ, Topor LS, Gillispie-Taylor M, Johnston LC, Beck Dallaghan GL, James SH, Moffatt ME, Sauer CG, Myers P, Myers A, Degnon L, Weiss P) J Pediatr 2025 Nov 05:114893 PMID: 41203114 SCOPUS ID: 2-s2.0-105025144306 11/08/2025 A Rising Tide Lifts All Boats: The Role of the Subspecialist in Recruitment into Pediatrics. (Lee-Kim Y, DelSignore L, Antos NJ, Morse CL, Kruger SJ, Topor LS, Gillispie-Taylor M, Johnston LC, Beck Dallaghan GL, James SH, Moffatt ME, Sauer CG, Myers P, Myers A, Degnon L, Weiss P) J Pediatr 2025 Oct;285:114757 PMID: 40738342 SCOPUS ID: 2-s2.0-105013652114 07/31/2025 4 CitationsClinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study. (Pittman JE, Morgan S, McCreary M, Vu PT, Jorth P, Heltshe S, Hoffman LR, Kelly A, Sagel SD, Singh PK, Solomon GM, Rosenfeld M, Ratjen F, PROMISE Pediatric substudy Investigators) Ann Am Thorac Soc 2025 Nov;22(11):1696-1708 PMID: 40540670 PMCID: PMC12393130 SCOPUS ID: 2-s2.0-105023106455 06/20/2025 2 CitationsCystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID-19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model. (Albon D, Ong T, Horton B, Brighton D, Shen S, List R, Antos N, Asfour F, Balasa E, Beachler D, Daines C, Froh D, Kier C, Nasr S, Sathe M, Sawicki G, Schechter M, Solomon G, Powers M) Pediatr Pulmonol 2025 May;60(5):e71102 PMID: 40325945 PMCID: PMC12052861 SCOPUS ID: 2-s2.0-105004476791 05/06/2025 3 CitationsThe Frequency and Potential Implications of HFE Genetic Variants in Children With Cystic Fibrosis. (Huang L, Lai HJ, Furuya KN, Antos NJ, Asfour F, Boyne KL, Howenstine M, Rock MJ, Sawicki GS, Gaffin JM, Worthey EA, Farrell PM) Pediatr Pulmonol 2025 Mar;60(3):e71042 PMID: 40071665 PMCID: PMC11898569 SCOPUS ID: 2-s2.0-105000307492 03/12/2025 Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis. (Liu C, Bach TR, Farrell PM, Pavelec D, Antos NJ, Rock MJ, Asfour F, Howenstine M, Gaffin JM, Lai HJ) J Pediatr Gastroenterol Nutr 2024 Dec;79(6):1124-1133 PMID: 39465618 PMCID: PMC11615133 SCOPUS ID: 2-s2.0-85207930569 10/28/2024 2 CitationsInterventions to improve system-level coproduction in the Cystic Fibrosis Learning Network. (Gamel B, Albon D, Bandla S, Davison DW, Flath J, Sabadosa KA, Seid M, Silva L, Ong T, Cystic Fibrosis Learning Network Group) BMJ Open Qual 2024 Jul 27;13(3) PMID: 39067867 PMCID: PMC11287073 SCOPUS ID: 2-s2.0-85199936319 07/28/2024 5 CitationsCystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS/CFSPID. (Green DM, Lahiri T, Raraigh KS, Ruiz F, Spano J, Antos N, Bonitz L, Christon L, Gregoire-Bottex M, Hale JE, Langfelder-Schwind E, La Parra Perez Á, Maguiness K, Massie J, McElroy-Barker E, McGarry ME, Mercier A, Munck A, Oliver KE, Self S, Singh K, Smiley M, Snodgrass S, Tluczek A, Tuley P, Lomas P, Wong E, Hempstead SE, Faro A, Ren CL) Pediatrics 2024 May 01;153(5) PMID: 38577740 PMCID: PMC11781860 SCOPUS ID: 2-s2.0-85192027867 04/05/2024 22 CitationsClinical outcomes at 9-10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome. (Carroll BJ, Ostrenga JS, Fink AK, Antos NJ, Cromwell EA, Ren CL) Pediatr Pulmonol 2024 Jun;59(6):1606-1613 PMID: 38477633 SCOPUS ID: 2-s2.0-85188106348 03/13/2024 2 CitationsA Cross-Sectional Study of Pediatric Feeding Disorder in Children with Cystic Fibrosis. (Bashir A, Antos N, Miller T, Challa SA, Pan AY, Gosa M, Silverman A, Goday PS) J Pediatr Gastroenterol Nutr 2023 Dec 01;77(6):819-823 PMID: 37771032 SCOPUS ID: 2-s2.0-85178570293 09/29/2023 3 CitationsRefinement of newborn screening for cystic fibrosis with next generation sequencing. (Rock MJ, Baker M, Antos N, Farrell PM) Pediatr Pulmonol 2023 Mar;58(3):778-787 PMID: 36416003 SCOPUS ID: 2-s2.0-85143973852 11/24/2022 33 CitationsDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. (Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH, SIMPLIFY Study Group) Lancet Respir Med 2023 Apr;11(4):329-340 PMID: 36343646 PMCID: PMC10065895 SCOPUS ID: 2-s2.0-85147655269 11/08/2022 114 CitationsDefining and identifying early-onset lung disease in cystic fibrosis with cumulative clinical characteristics. (Huang L, Lai HJ, Antos N, Rock MJ, Asfour F, Howenstine M, Gaffin JM, Farrell PM) Pediatr Pulmonol 2022 Oct;57(10):2363-2373 PMID: 35712759 PMCID: PMC9489630 SCOPUS ID: 2-s2.0-85132588336 06/18/2022 9 CitationsCystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting. (Albon D, Thomas L, Hoberg L, Stamper S, Somerville L, Varghese P, Balasa E, Roman M, Britto MT, Miner M, Gehring E, Gammon C, Amin RS, Seid M, Powers M, CF Learning Network telehealth iLab working group) BMJ Open Qual 2022 May;11(2) PMID: 35589277 PMCID: PMC9121114 SCOPUS ID: 2-s2.0-85130313310 05/20/2022 16 CitationsTesting the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. (Nichols DP, Singh PK, Baines A, Caverly LJ, Chmiel JF, GIbson RL, Lascano J, Morgan SJ, Retsch-Bogart G, Saiman L, Sadeghi H, Billings JL, Heltshe SL, Kirby S, Kong A, Nick JA, Mayer-Hamblett N, TEACH Study Group) Thorax 2022 Jun;77(6):581-588 PMID: 34706982 PMCID: PMC9043040 SCOPUS ID: 2-s2.0-85125627383 10/29/2021 20 CitationsCystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation. (Antos NJ, Savant AP) Pediatr Pulmonol 2022 Feb;57(2):347-360 PMID: 34033706 SCOPUS ID: 2-s2.0-85106317899 05/26/2021 6 CitationsQuality Improvement Approach to Reducing Admission Hypothermia Among Preterm and Term Infants. (Sprecher A, Malin K, Finley D, Lembke P, Keller S, Grippe A, Hornung G, Antos N, Uhing M) Hosp Pediatr 2021 Mar;11(3):270-276 PMID: 33627479 SCOPUS ID: 2-s2.0-85133183735 02/26/2021 16 CitationsLong-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. (Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE, VX14-661-110 study group) Lancet Respir Med 2021 Jul;9(7):733-746 PMID: 33581080 SCOPUS ID: 2-s2.0-85101679537 02/14/2021 50 CitationsLumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. (Moheet A, Beisang D, Zhang L, Sagel SD, VanDalfsen JM, Heltshe SL, Frederick C, Mann M, Antos N, Billings J, Rowe SM, Moran A, PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network) J Cyst Fibros 2021 Mar;20(2):333-338 PMID: 32917547 PMCID: PMC7937760 SCOPUS ID: 2-s2.0-85090490297 09/13/2020 52 CitationsLactation Consultation Sustains Breast Milk Intake in Infants With Cystic Fibrosis. (Miller T, Antos NJ, Brock LA, Wade T, Goday PS) J Pediatr Gastroenterol Nutr 2019 Sep;69(3):358-362 PMID: 31181018 SCOPUS ID: 2-s2.0-85070818417 06/11/2019 11 CitationsOral health of cystic fibrosis patients at a north american center: A pilot study. (Abu-Zahra R, Antos NJ, Kump T, Angelopoulou MV) Med Oral Patol Oral Cir Bucal 2019 May 01;24(3):e379-e384 PMID: 31011138 PMCID: PMC6530948 SCOPUS ID: 2-s2.0-85065512008 04/24/2019 17 CitationsBuilding school health partnerships to improve pediatric asthma care: the School-based Asthma Management Program. (Kakumanu S, Antos N, Szefler SJ, Lemanske RF Jr) Curr Opin Allergy Clin Immunol 2017 Apr;17(2):160-166 PMID: 28177950 SCOPUS ID: 2-s2.0-85011840277 02/09/2017 24 CitationsCreation and implementation of SAMPRO™: A school-based asthma management program. (Lemanske RF Jr, Kakumanu S, Shanovich K, Antos N, Cloutier MM, Mazyck D, Phipatanakul W, Schantz S, Szefler S, Vandlik R, Williams P) J Allergy Clin Immunol 2016 Sep;138(3):711-723 PMID: 27596707 PMCID: PMC5085063 SCOPUS ID: 2-s2.0-84995460912 09/07/2016 83 CitationsImproving inpatient cystic fibrosis pulmonary exacerbation care: two success stories. (Antos NJ, Quintero DR, Walsh-Kelly CM, Noe JE, Schechter MS) BMJ Qual Saf 2014 Apr;23 Suppl 1:i33-i41 PMID: 24608549 SCOPUS ID: 2-s2.0-84896535767 03/13/2014 11 CitationsImplementing Inpatient Cystic Fibrosis Related Diabetes Screening: Successes and a Resultant Epidemic. (Antos, Nicholas J; Miller, T; Walsh-Kelly, C; Noe, J; Quintero, D.) Pediatric Pulmonology [Abstract] Vol 48, Issue S36, Oct 2013: A496 10/01/2013 Barriers To Initial Administration Of Airway Clearance Therapy In Pediatric Cystic Fibrosis Hospitalizations (Antos, Nicholas J; Walsh-Kelly, CD; Quintero, DR) Am J Respir Crit Care Med. [Abstract]. May 2013. 187: A3887 05/01/2013
© 2026 Clinical & Translational Science Institute